<DOC>
	<DOCNO>NCT01815840</DOCNO>
	<brief_summary>This randomize , double-blind , regimen-controlled , phase II , multicenter study assess efficacy safety two different vismodegib regimens participant multiple basal cell carcinoma . Participants receive vismodegib 150 mg orally daily either intermittent schedule 12 week vismodegib follow 8 week placebo ( Arm A ) 24 week induction follow intermittent schedule 8 week placebo follow 8 week vismodegib ( Arm B ) . Anticipated time study treatment 72 week .</brief_summary>
	<brief_title>A Study Two Vismodegib Regimens Participants With Multiple Basal Cell Carcinomas</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Basal Cell Nevus Syndrome</mesh_term>
	<mesh_term>Hamartoma Syndrome , Multiple</mesh_term>
	<criteria>Adult participant , &gt; /= 18 year age Participants multiple basal cell carcinoma , include participant Gorlin syndrome , least 6 clinically evident basal cell carcinoma time randomization , 3 measure 5 mm diameter consider target lesion . All lesion consider nontarget lesion Histopathologic confirmation least one three target lesion basal cell carcinoma Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Adequate renal hepatic function hematopoietic capacity Women childbearing potential must agree use contraception define protocol treatment least 9 month completion study treatment Male participant female partner childbearing potential must agree use contraception define protocol treatment 2 month completion study treatment Inability unwillingness swallow capsule Pregnant breastfeed woman Any metastatic basal cell carcinoma Locally advance basal cell carcinoma lesion consider inoperable medical contraindication surgery Recent ( i.e. , within past 28 day prior randomization ) current participation another experimental drug study Known suspect alcohol abuse One follow know rare hereditary condition : galactose intolerance , primary hypolactasia glucosegalactose malabsorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>